Literature DB >> 7057813

"Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients.

R A Kyle, P R Greipp.   

Abstract

We studied seven patients with idiopathic Bence Jones proteinuria (excretion greater than 1.0 g per 24 hours) who did not have acquired Fanconi's syndrome or an intact monoclonal immunoglobulin in the serum. None had evidence of overt multiple myeloma, of its variants, of systemic amyloidosis, or of malignant lymphoproliferative diseases when the proteinuria was recognized. In three of the seven patients, symptomatic multiple myeloma (associated with systemic amyloidosis in one) developed 8.8 to 21.1 years later. A fourth patient has asymptomatic myeloma and has not been treated. A fifth patient had an evolving myeloma at nine years but died of an unrelated cause. The remaining two patients still have apparently benign Bence Jones proteinuria after 7.7 and 12 years. Plasma-cell labeling indexes were low in all cases tested. This experience shows that although idiopathic Bence Jones proteinuria may remain stable for years, multiple myeloma or amyloidosis often develops, and consequently these patients must be kept under observation indefinitely.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7057813     DOI: 10.1056/NEJM198203113061002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  10 in total

1.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

2.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

3.  The kidney in myeloma.

Authors:  T J Hamblin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

4.  Laboratory investigation of paraproteinaemia.

Authors:  P G Riches; J R Hobbs
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

5.  Renal impairment in myeloma: negative association with isoelectric point of excreted Bence-Jones protein.

Authors:  A G Norden; F V Flynn; L M Fulcher; J D Richards
Journal:  J Clin Pathol       Date:  1989-01       Impact factor: 3.411

6.  Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.

Authors:  Robert A Kyle; Dirk R Larson; Terry M Therneau; Angela Dispenzieri; L Joseph Melton; Joanne T Benson; Shaji Kumar; S Vincent Rajkumar
Journal:  Lancet Haematol       Date:  2014-10-01       Impact factor: 18.959

7.  Adult Fanconi syndrome progressing to multiple myeloma.

Authors:  R L Sewell; M S Dorreen
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

Review 8.  Deposition-associated diseases related with a monoclonal compound.

Authors:  M J Molina-Garrido; C Guillén-Ponce; A Mora; M Guirado-Risueño; M A Molina; M J Molina; A Carrato
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

9.  Clinical profile of kidney involvement preceding diagnosis of multiple myeloma; a single center experience.

Authors:  Manish R Balwani; Manoj R Gumber; Pankaj R Shah; Vivek B Kute; Himanshu V Patel; Divyesh P Engineer; Dinesh N Gera; Umesh Godhani; Rajesh Singh Gautam; Hargovind L Trivedi
Journal:  J Nephropharmacol       Date:  2015-03-29

10.  Monoclonal immunoglobulin light chain in urine of patients with B lymphocytic disease: its source and use as a diagnostic aid.

Authors:  F K Stevenson; M Spellerberg; J L Smith
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.